StockData
Taysha Gene Therapies, Inc. logo

Taysha Gene Therapies, Inc. (TSHA) stock

TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$4.00−0.06 (-1.48%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

Taysha Gene Therapies cash

Cash and short-term investments held at the end of each period.

Taysha Gene Therapies's cash was $455.41M at Jun 30, 2026. For fiscal 2025 it was $319.77M, up 130.0% from the year before. The highest annual figure on record is $319.77M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$319.77M+130.0%
FY2024Dec 31, 2024$139.04M-3.4%
FY2023Dec 31, 2023$143.94M+63.8%
FY2022Dec 31, 2022$87.88M-41.1%
FY2021Dec 31, 2021$149.10M-40.7%
FY2020Dec 31, 2020$251.25M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$455.41M+45.6%
Q1 FY2026Mar 31, 2026$276.58M+137.2%
Q4 FY2025Dec 31, 2025$319.77M+130.0%
Q3 FY2025Sep 30, 2025$297.34M+88.6%
Q2 FY2025Jun 30, 2025$312.76M+81.1%
Q1 FY2025Mar 31, 2025$116.59M-6.0%
Q4 FY2024Dec 31, 2024$139.04M-3.4%
Q3 FY2024Sep 30, 2024$157.69M-4.0%
Q2 FY2024Jun 30, 2024$172.74M+283.2%
Q1 FY2024Mar 31, 2024$123.98M+95.5%
Q4 FY2023Dec 31, 2023$143.94M+63.8%
Q3 FY2023Sep 30, 2023$164.28M+378.9%
Q2 FY2023Jun 30, 2023$45.08M-31.9%
Q1 FY2023Mar 31, 2023$63.43M-34.4%
Q4 FY2022Dec 31, 2022$87.88M-41.1%
Q3 FY2022Sep 30, 2022$34.31M-81.8%
Q2 FY2022Jun 30, 2022$66.24M-66.4%
Q1 FY2022Mar 31, 2022$96.63M-57.7%
Q4 FY2021Dec 31, 2021$149.10M-40.7%
Q3 FY2021Sep 30, 2021$188.79M-32.2%
Q2 FY2021Jun 30, 2021$197.37M–
Q1 FY2021Mar 31, 2021$228.68M–
Q4 FY2020Dec 31, 2020$251.25M–
Q3 FY2020Sep 30, 2020$278.63M–

More Taysha Gene Therapies figures

See a number that looks wrong?